These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31688976)

  • 1. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
    Shamash J; Mee M; Sarker SJ; Wilson P; Ansell W; Greenwood M; Berney D; Alifrangis C
    BJU Int; 2020 Jun; 125(6):843-852. PubMed ID: 31688976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
    Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ;
    Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GAMEC--a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours.
    Shamash J; Powles T; Ansell W; Berney D; Stebbing J; Mutsvangwa K; Wilson P; Asterling S; Liu S; Wyatt P; Joel SP; Oliver RT
    Br J Cancer; 2007 Aug; 97(3):308-14. PubMed ID: 17609665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
    Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
    Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG).
    Berger LA; Bokemeyer C; Lorch A; Hentrich M; Kopp HG; Gauler TC; Beyer J; de Wit M; Mayer F; Boehlke I; Oing C; Honecker F; Oechsle K
    J Cancer Res Clin Oncol; 2014 Jul; 140(7):1211-20. PubMed ID: 24696231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain metastases associated with germ cell tumors may be treated with chemotherapy alone.
    Hardt A; Krell J; Wilson PD; Harding V; Chowdhury S; Mazhar D; Berney D; Stebbing J; Shamash J
    Cancer; 2014 Jun; 120(11):1639-46. PubMed ID: 24668504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
    Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
    Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.
    Fizazi K; Le Teuff G; Fléchon A; Pagliaro L; Mardiak J; Geoffrois L; Laguerre B; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Cancel M; Juzyna B; Reckova M; Naoun N; Logothetis C; Culine S
    J Clin Oncol; 2024 Oct; 42(28):3270-3276. PubMed ID: 39167741
    [No Abstract]   [Full Text] [Related]  

  • 12. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.
    Necchi A; Mariani L; Di Nicola M; Lo Vullo S; Nicolai N; Giannatempo P; Raggi D; Farè E; Magni M; Piva L; Matteucci P; Catanzaro M; Biasoni D; Torelli T; Stagni S; Bengala C; Barone C; Schiavetto I; Siena S; Carlo-Stella C; Pizzocaro G; Salvioni R; Gianni AM
    Ann Oncol; 2015 Jan; 26(1):167-172. PubMed ID: 25344361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
    Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J
    BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours.
    Anthoney DA; McKean MJ; Roberts JT; Hutcheon AW; Graham J; Jones W; Paul J; Kaye SB
    Br J Cancer; 2004 Feb; 90(3):601-6. PubMed ID: 14760371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleomycin, etoposide and cisplatinum (BEP) chemotherapy for metastatic germ cell tumours: treatment outcomes at UKM medical centre, Malaysia.
    Azrif M; Leong YK; Aslan NM; Fong KV; Ismail F
    Asian Pac J Cancer Prev; 2012; 13(6):2467-71. PubMed ID: 22938405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
    Marwaha S; Venner PM; North SA
    Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
    Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
    J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.